IQVIA Holdings(IQV)
$245.82-4.73 (-1.89%)
IQV
IQVIA Holdings stock drug pipeline
$245.82
At close:-4.73 (-1.89%)
Want to see IQV full AI Analyst Report?
IQVIA Holdings (IQV) Drug Pipeline
1,105 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does IQVIA Holdings (IQV) have in its pipeline
IQVIA Holdings IQV is currently developing the following drugs: Pegcetacoplan, Apl-2, Pegcetacoplan, Noc-110, Atozet 10/40 Mg Or 10/80 Mg, Lipitor 40 Mg Or 80 Mg, Avt05, Simponi, Og-6219, Olorofim, Ambisome, Paclitaxel, Carboplatin, Oregovomab, Pembrolizumab, Ctx-471, Imr-687, 3 G Or 6 G Zidebactam, Leo 90105 = Calcipotriol + Betamethasone Dipropionate, Dovonex = Calcipotriol, Rinderon - Dp = Betamethasone Dipropionate, Leo 90105. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

